McInnes et al. 24 week phase 2 ARGO trial. Sonelokimab, IL-17A- and IL-17F-inhibiting nanobody, in PsA. ACR50 responses
Tweet Content
McInnes et al. 24 week phase 2 ARGO trial. Sonelokimab, IL-17A- and IL-17F-inhibiting nanobody, in PsA. ACR50 responses shown in picture. Good efficacy across domains, but this is phase 2, will await the phase 3. @RheumNow #ACR24 Abstr#2582 https://t.co/FQflZMPes0 https://t.co/DATqo37yib
Links
Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanob…
https://acrabstracts.org/abstract/efficacy-and-safety-of-sonelokimab-a-novel-il…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off